In the study, researchers proposed using targeted micro RNA therapy to reduce the incidence of secondary cataracts by stopping them before they start developing.
The results of the study, published in Molecular Medicine, provide a “roadmap for potential therapies that control miRNA expression for the prevention of secondary cataracts,” according to the release.
The study was conducted in the University of Dayton’s Center for Tissue Regeneration and Engineering at Dayton, with Panagiotis Tsonis, PhD, biology professor and the center’s director as the principal investigator.
Related Articles on Cataracts:
NV’s New Eyes Now Offers LenSx Laser Cataract Surgery
Ophthalmologist on the Move: Dr. Kevin H. Merkley Joins TX’s UTMB Health Eye Center
Laser Cataract Surgery of New York Offers LenSx Surgery
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
